Form 4: Supernus Pharmaceuticals Director Carrolee Barlow Acquires Stock Options and Restricted Stock Units

Director Carrolee Barlow acquired stock options and restricted stock units in Supernus Pharmaceuticals on February 19, 2025.

Summary

• On February 19, 2025, Carrolee Barlow, a director of Supernus Pharmaceuticals, acquired stock options and restricted stock units.
• The stock options grant the right to purchase 7,296 shares of common stock at an exercise price of $33.52, vesting on February 19, 2026, and expiring on February 19, 2035.
• Barlow also acquired 4,475 restricted stock units, each representing the right to receive one share of Supernus common stock upon vesting on February 19, 2026.
• Following these transactions, Barlow directly owns 17,201 shares of Supernus common stock, 7,296 stock options, and 4,475 restricted stock units.

Sentiment

Score: 7

Explanation: Director's acquisition of stock options and restricted stock units is generally a positive sign, indicating confidence in the company's future prospects. However, it's a routine transaction and doesn't provide significant new information.

Positives

• The acquisition of stock options and restricted stock units by a director signals confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements, but the acquisition of equity suggests an expectation of future value appreciation.

Industry Context

Director stock acquisitions are common in the pharmaceutical industry as a way to incentivize management and align their interests with shareholders.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Supernus Pharmaceuticals, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, SUPN